Solara Active Pharma Sciences Limited
NSE: SOLARA BSE: SOLARA
NSE
469.75
19.45 (4.32%)
Prev Close
450.3
Open Price
449.8
Volume
100,544
Today Low / High
442.8 / 472.8
52 WK Low / High
355.1 / 882.8
Range
446 - 493
BSE
472.50
22.40 (4.98%)
Prev Close
450.1
Open Price
441.1
Volume
4,827
Today Low / High
441.1 / 472.6
52 WK Low / High
355.3 / 885.95
Range
449 - 496
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 469.75 (target range: 446 - 493), reflecting a change of 19.45 (4.31934%). On the BSE, it is listed at 472.5 (target range: 449 - 496), showing a change of 22.4 (4.97667%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
04 Mar
449.80
4.46%
03 Mar
475.95
-5.39%
28 Feb
469.90
0.57%
27 Feb
482.00
-2.48%
25 Feb
476.00
3.77%
24 Feb
477.05
-0.24%
21 Feb
479.95
2.32%
20 Feb
457.85
2.22%
19 Feb
473.05
-3.17%
18 Feb
509.90
-5.50%
17 Feb
494.00
2.67%
14 Feb
508.80
-3.60%
13 Feb
514.80
-2.88%
12 Feb
522.00
-3.52%
11 Feb
534.95
-2.65%
10 Feb
534.80
-0.55%
07 Feb
561.70
-4.95%
06 Feb
539.95
0.61%
05 Feb
536.70
-0.47%
04 Feb
529.95
0.43%
Solara Active Pharma Sciences Limited Graph
Solara Active Pharma Sciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking Target Price for Solara Active Pharma Sciences Limited T1, T2, T3, for both Bullish or Bearish. For Bullish T1, T2, T3 and for Bearish T1, T2, T3. The stock current price is 470, with potential price targets ranging from T1, T2, T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 472.50 | 477.23 | 429.50 - 524.95 |
| 481.95 | 385.56 - 578.34 | ||
| 486.68 | 340.67 - 632.68 | ||
| Bearish Scenario | 472.50 | 467.78 | 421.00 - 514.55 |
| 463.05 | 370.44 - 555.66 | ||
| 458.33 | 320.83 - 595.82 |
Overview of Solara Active Pharma Sciences Limited
ISIN
INE624Z01016
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
137,172
Market Cap
23,567,619,004
Last Dividend
0
Official Website
IPO Date
2018-06-27
DCF Diff
1,645.75
DCF
-818
Financial Ratios Every Investor Needs
Stock Dividend of SOLARA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2021-08-18 | August 18, 21 | 3 | 3 | 2021-08-20 | 2021-09-24 | |
| 2020-11-19 | November 19, 20 | 4 | 4 | 2020-11-20 | 2020-12-11 | |
| 2020-07-28 | July 28, 20 | 2 | 2 | 2020-07-29 | 2020-09-03 | 2020-05-07 |
| 2019-08-06 | August 06, 19 | 5 | 5 | 2019-08-07 | 2019-09-13 | 2019-05-16 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,238.39 Cr | 1,403.98 Cr | -165.59 Cr | -0.1337 | 0.00 Cr | 24.33 Cr | -385.29 Cr | -567.39 Cr | -145.27 | -282.19 Cr | -0.4582 |
| 2023-03-31 | 1,443.81 Cr | 788.82 Cr | 654.99 Cr | 0.4537 | 46.16 Cr | 229.92 Cr | 27.59 Cr | -22.17 Cr | -6.16 | 152.36 Cr | -0.0154 |
| 2022-03-31 | 1,230.55 Cr | 697.79 Cr | 532.76 Cr | 0.4329 | 65.62 Cr | 31.03 Cr | -25.99 Cr | -58.15 Cr | -16.18 | 88.50 Cr | -0.0473 |
| 2021-03-31 | 1,575.73 Cr | 769.58 Cr | 806.15 Cr | 0.5116 | 64.35 Cr | 32.85 Cr | 284.60 Cr | 221.40 Cr | 69.00 | 413.85 Cr | 0.1405 |
| 2020-03-31 | 1,267.64 Cr | 640.73 Cr | 626.91 Cr | 0.4945 | 58.57 Cr | 28.34 Cr | 173.18 Cr | 114.61 Cr | 44.29 | 285.93 Cr | 0.0904 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 8.44 Cr | 2,350.96 Cr | 1,414.38 Cr | 933.9100 Cr | 1,011.50 Cr | 1,003.06 Cr | 359.70 Cr | 1,114.22 Cr | 4.19 Cr | 0.00 Cr | 1.70 Cr | 1,242.8500 Cr |
| 2023-03-31 | 8.73 Cr | 2,899.06 Cr | 1,396.60 Cr | 1,500.2200 Cr | 1,012.85 Cr | 1,004.12 Cr | 558.09 Cr | 1,159.05 Cr | 16.01 Cr | -83.31 Cr | 1.70 Cr | 1,100.9000 Cr |
| 2022-03-31 | 46.38 Cr | 2,952.53 Cr | 1,425.35 Cr | 1,524.8700 Cr | 1,037.37 Cr | 990.99 Cr | 575.55 Cr | 1,160.12 Cr | 38.40 Cr | 23.13 Cr | 0.42 Cr | 1,070.9900 Cr |
| 2021-03-31 | 197.69 Cr | 2,613.58 Cr | 1,020.82 Cr | 1,588.5200 Cr | 620.73 Cr | 423.04 Cr | 294.97 Cr | 1,038.86 Cr | 20.29 Cr | 28.49 Cr | 0.42 Cr | 788.7500 Cr |
| 2020-03-31 | 56.04 Cr | 2,153.50 Cr | 1,063.27 Cr | 1,085.9400 Cr | 722.01 Cr | 665.97 Cr | 279.73 Cr | 964.98 Cr | 31.95 Cr | 42.74 Cr | 0.32 Cr | 729.8900 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 108.8700 Cr | -3.5100 Cr | -105.6500 Cr | 67.8100 Cr | -0.2900 Cr | 8.4400 Cr | -41.0600 Cr | -488.4200 Cr | -114.4700 Cr | 0.0000 Cr | 13.0800 Cr |
| 2023-03-31 | 156.2500 Cr | -81.1400 Cr | -112.7600 Cr | 44.9400 Cr | -37.6500 Cr | 8.7300 Cr | -111.3100 Cr | -44.8100 Cr | -64.7500 Cr | 0.0000 Cr | 17.3200 Cr |
| 2022-03-31 | -242.0300 Cr | -242.8500 Cr | 333.5700 Cr | -450.6500 Cr | -151.3100 Cr | 46.3800 Cr | -208.6200 Cr | -91.1000 Cr | 166.1800 Cr | -10.7800 Cr | -280.5800 Cr |
| 2021-03-31 | 155.4600 Cr | -106.3000 Cr | 92.4900 Cr | -19.0200 Cr | 141.6500 Cr | 197.6900 Cr | -174.4800 Cr | 221.5000 Cr | -100.1500 Cr | -19.7300 Cr | -15.2400 Cr |
| 2020-03-31 | 244.2200 Cr | -358.8100 Cr | 94.9100 Cr | -24.6500 Cr | -19.6800 Cr | 56.0400 Cr | -268.8700 Cr | 114.9100 Cr | 163.5600 Cr | -15.6200 Cr | -65.7900 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 300.31 Cr | 134.86 Cr | 165.45 Cr | 0.5509 | 0.00 Cr | 8.09 Cr | 2.03 | 59.17 Cr | 0.0269 |
| 2024-09-30 | 346.95 Cr | 249.94 Cr | 97.01 Cr | 0.2796 | 35.97 Cr | 8.01 Cr | 1.67 | 61.63 Cr | 0.0231 |
| 2024-06-30 | 363.49 Cr | 281.66 Cr | 81.83 Cr | 0.2251 | 16.85 Cr | -13.46 Cr | -3.50 | 42.48 Cr | -0.0370 |
| 2024-03-31 | 262.64 Cr | 159.98 Cr | 102.66 Cr | 0.3909 | -13.79 Cr | -255.34 Cr | -65.37 | -110.72 Cr | -0.9722 |
| 2023-12-31 | 248.73 Cr | 304.12 Cr | -55.39 Cr | -0.2227 | -187.65 Cr | -275.34 Cr | -76.49 | -224.01 Cr | -1.1070 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 5.91 Cr | 12.16 Cr | 18.07 Cr | 0.00 Cr | 289.71 Cr | 759.38 Cr | 1,099.18 Cr | 2,289.78 Cr | 1,201.09 Cr |
| 2024-06-30 | -8.60 Cr | 17.20 Cr | 8.60 Cr | 0.00 Cr | 0.00 Cr | 8.60 Cr | 0.00 Cr | 0.00 Cr | -936.58 Cr |
| 2024-03-31 | 8.32 Cr | 7.58 Cr | 15.90 Cr | 348.52 Cr | 359.70 Cr | 790.65 Cr | 1,107.61 Cr | 2,346.60 Cr | 1,409.18 Cr |
| 2023-12-31 | -6.46 Cr | 12.92 Cr | 6.46 Cr | 0.00 Cr | 0.00 Cr | 6.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 6.30 Cr | 14.69 Cr | 20.99 Cr | 525.86 Cr | 556.88 Cr | 1,194.98 Cr | 1,125.41 Cr | 2,875.33 Cr | 1,409.12 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | -13.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -255.34 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | -274.80 Cr | 51.92 Cr | 0.00 Cr | 0.00 Cr | 51.92 Cr | 58.38 Cr | 6.46 Cr | 0.00 Cr | 51.92 Cr |
| 2023-09-30 | -17.16 Cr | 52.42 Cr | 0.00 Cr | 0.00 Cr | 52.42 Cr | 6.46 Cr | -45.96 Cr | 0.00 Cr | 52.42 Cr |
| 2023-06-30 | -19.55 Cr | 51.82 Cr | 0.00 Cr | 0.00 Cr | 51.82 Cr | 60.71 Cr | 8.89 Cr | 0.00 Cr | 51.82 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2024-05-15 | May 15, 24 | 217:200 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,558.65 | ₹3,739,637,772,000.00 | ₹781,719.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,506.25 | ₹1,461,738,681,250.00 | ₹64,908.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹2,949.60 | ₹998,277,372,000.00 | ₹166,276.00 |
| Mankind Pharma Limited | MANKIND | ₹2,291.25 | ₹945,320,533,950.00 | ₹177,711.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,114.75 | ₹928,700,476,795.00 | ₹434,095.00 |
| Lupin Limited | LUPIN | ₹1,934.60 | ₹883,108,142,600.00 | ₹259,741.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹870.20 | ₹875,621,346,000.00 | ₹343,556.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,050.85 | ₹610,335,781,700.00 | ₹413,280.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,591.20 | ₹548,946,828,000.00 | ₹17,608.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,313.55 | ₹370,668,047,400.00 | ₹97,865.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,339.40 | ₹339,811,137,600.00 | ₹56,310.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,451.70 | ₹306,246,750,400.00 | ₹61,223.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,161.90 | ₹295,779,073,500.00 | ₹165,600.00 |
| Laurus Labs Limited | LAURUSLABS | ₹541.60 | ₹292,059,424,800.00 | ₹1,255,902.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,614.85 | ₹251,280,349,100.00 | ₹29,467.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,238.20 | ₹201,165,401,200.00 | ₹280,998.00 |
| Piramal Enterprises Limited | PEL | ₹877.00 | ₹197,744,206,000.00 | ₹172,994.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹7,180.00 | ₹179,500,000,000.00 | ₹18,235.00 |
| Eris Lifesciences Limited | ERIS | ₹1,181.00 | ₹160,768,349,000.00 | ₹22,410.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹775.65 | ₹152,464,090,950.00 | ₹312,147.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹917.85 | ₹146,196,065,850.00 | ₹70,165.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹11,307.10 | ₹145,068,962,290.00 | ₹40,103.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹801.90 | ₹143,628,309,000.00 | ₹553,341.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,794.05 | ₹136,368,790,385.00 | ₹351,707.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹474.45 | ₹115,051,278,300.00 | ₹761,172.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,120.00 | ₹84,988,928,000.00 | ₹2,119.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹733.60 | ₹66,483,240,936.00 | ₹180,483.00 |
| FDC Limited | FDC | ₹380.40 | ₹61,932,924,000.00 | ₹76,550.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹623.30 | ₹60,953,067,970.00 | ₹158,952.00 |
| Strides Pharma Science Limited | STAR | ₹606.80 | ₹55,924,326,360.00 | ₹175,466.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹912.85 | ₹46,298,930,435.00 | ₹61,199.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹630.35 | ₹44,380,296,030.00 | ₹15,929.00 |
| Hikal Limited | HIKAL | ₹353.10 | ₹43,537,583,100.00 | ₹104,019.00 |
| Innova Captab Limited | INNOVACAP | ₹676.60 | ₹38,718,387,638.00 | ₹65,536.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹117.03 | ₹37,978,809,660.00 | ₹840,880.00 |
| Sequent Scientific Limited | SEQUENT | ₹145.38 | ₹36,388,904,760.00 | ₹484,563.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,080.00 | ₹34,401,120,000.00 | ₹13,355.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹316.20 | ₹31,707,903,600.00 | ₹60,257.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹346.80 | ₹31,652,436,000.00 | ₹50,219.00 |
| Suven Life Sciences Limited | SUVEN | ₹116.15 | ₹25,329,295,100.00 | ₹387,876.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹45.64 | ₹25,008,620,560.00 | ₹2,413,022.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹469.75 | ₹23,648,166,244.00 | ₹100,544.00 |
| Alembic Limited | ALEMBICLTD | ₹89.77 | ₹23,051,320,050.00 | ₹318,318.00 |
| Indoco Remedies Limited | INDOCO | ₹226.93 | ₹20,933,815,947.00 | ₹228,598.00 |
| Bajaj HealthCare Limited | BAJAJHCARE | ₹635.05 | ₹20,056,974,665.00 | ₹289,638.00 |
Key Executives
Chief Scientific Officer
Dr. Hero Velladurai
Gender: Not Specified
Year Born:
Chief Quality Officer
Mr. V. Sundara Moorthy
Gender: male
Year Born:
Chief Executive Officer & MD
Mr. Sandeep Rao M.Sc., PGDM
Gender: male
Year Born: 1973
Founder & Non-Executive Director
Mr. Arun Kumar Pillai B.Com.
Gender: male
Year Born: 1961
Chief Operating Officer & Executive Director
Mr. Mohan Muthunarayanan
Gender: male
Year Born:
Company Secretary, Compliance Officer & Chief Investor Relations Officer
Mr. Suddapalli Murali Krishna
Gender: male
Year Born:
Chief Financial Officer
Mr. Sarat Kumar
Gender: male
Year Born:
Chief Business Officer
Mr. Vishal Mathur
Gender: male
Year Born:
FAQs about Solara Active Pharma Sciences Limited
Who is the CEO of the company?
The CEO is Mr. Sandeep Rao M.Sc., PGDM.
What is the current market price of the stock?
The current price is ₹468.15.
What is the 52-week price range?
The range is ₹355.1-882.8.
What is the market capitalization of the company?
The market capitalization is ₹2,356.76 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -7.38.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Solara Active Pharma Sciences Limited (ISIN: INE624Z01016) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,356.76 crores and an average daily volume of 137,172 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.